UbiQ Therapeutics


UbiQ Therapeutics, a business division of UbiQ, was established in 2015 with the aim to expand UbiQ’s drug discovery efforts by teaming up with pharma partners


mission

Discovering the therapeutic value of the ubiquitin system.

 

focus

  • Creating value in our first Triple E program: R107, a mechanism-based covalent SUMOylation inhibitor: This program is conducted in our joint venture with Mercachem: SumiQ Therapeutics (www.sumiqtx.com)
  • Building a pipeline of mechanism-based covalent ubiquitin(-like) cascade inhibitors, based on our Triple E platform.

 

proprietary position

A patent application on the Triple E Platform technology has been filed in 2014, one in the EU and a provisional application in the US. 


contact

For more information on our drug discovery programs please contact Boris Rodenko, our VP Translational Drug Discovery borisrodenko[at]UbiQbio.com
For more information on our SUMOylation inhibitor: www.sumiqtx.com

 

development pipeline 

project target indication drug discovery  pre-clinical clinical
UbiQ-R106  undisclosed ubiquitin-like cascade cancer

 

pijl 1

   

UbiQ-R107

(in SumiQ)

SUMOylation cascade 

cancer

 

pijl2 

 

 
UbiQ-R108

undisclosed ubiquitin-like cascade

cancer 

 

pijl4